ProKidney Corp. reported its financial results for the third quarter of 2025, revealing a revenue of $217,000 for the three months ended September 30, 2025, compared to no revenue in the same period of the previous year. For the nine months ended September 30, 2025, the company generated $668,000 in revenue, marking a significant milestone as it had not reported any revenue in the prior year. Despite this revenue generation, ProKidney continued to experience substantial operating losses, reporting a net loss of $35.8 million for the third quarter, a decrease from a loss of $41.1 million in the same quarter of 2024. For the nine-month period, the net loss was $110.8 million, down from $114.9 million in the previous year.
The company’s operating expenses for the third quarter totaled $38.8 million, a decrease from $49.0 million in the same quarter of 2024. This reduction was primarily attributed to lower research and development costs, which fell to $26.8 million from $31.3 million, and a decrease in general and administrative expenses, which dropped to $11.9 million from $17.7 million. The decline in research and development expenses was largely due to the completion of certain clinical trials and a reduction in manufacturing improvement costs. The company also reported a decrease in interest income, which fell to $3.3 million from $5.6 million, reflecting lower investment balances and interest rates.
In terms of strategic developments, ProKidney completed a domestication process on July 1, 2025, transitioning its jurisdiction of incorporation from the Cayman Islands to Delaware. This move was part of a broader restructuring that included the formation of ProKidney Holdings, LLC, which now owns all subsidiaries conducting the company’s business. The restructuring is expected to streamline operations and enhance tax efficiency. Additionally, ProKidney is advancing its lead product candidate, rilparencel, which is currently in a Phase 3 clinical trial aimed at preserving kidney function in patients with chronic kidney disease and type 2 diabetes.
Operationally, ProKidney has made progress in its clinical trials, with over half of the required patients enrolled in the ongoing Phase 3 PROACT 1 study. The company anticipates topline data readout in the second quarter of 2027, which could support an application for accelerated approval from the FDA. As of September 30, 2025, ProKidney had cash and cash equivalents of $95.3 million, down from $99.1 million at the end of 2024, indicating a need for continued funding to support its operations and clinical development efforts.
Looking ahead, ProKidney expects its expenses to increase significantly as it continues to invest in the development of rilparencel and other potential product candidates. The company has indicated that it will require substantial additional funding to support its operations and growth strategy, which may involve public or private equity sales, debt financing, or strategic collaborations. The management remains cautious about the timing and success of its product development efforts, emphasizing the uncertainties inherent in the biotechnology sector.
About PROKIDNEY CORP.
ProKidney Corp. is a clinical-stage biotechnology company developing autologous cell therapies to treat chronic kidney disease (CKD). Its lead product, rilparencel, uses patient-derived kidney cells to preserve kidney function and delay progression to end-stage renal disease. The company focuses on regenerative medicine, clinical trials, and manufacturing personalized therapies, targeting markets with high unmet needs in CKD management and aiming for regulatory approval and commercialization.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.